Novo Nordisk challenges CMS drug price negotiations, then signs on to the program

Novo Nordisk has joined the long list of biopharma companies that are challenging drug price negotiation provisions in the Inflation Reduction Act (IRA).

Novo filed a lawsuit in federal district court in New Jersey on Friday, claiming that the program violates the First Amendment and Fifth Amendment.